Tetrabenazine.
BACKGROUND
Tetrabenazine (TBZ) depletes presynaptic dopamine in the CNS. It has been found to be beneficial in hyperkinetic movement disorders without carrying the extrapyramidal side effects that are characteristic of neuroleptics.


OBJECTIVE
To summarize current knowledge on the use of TBZ and draw conclusions about its efficacy and safety.


METHODS
PubMed literature searches using the term 'tetrabenazine' were carried out for the period prior to May 2009. Additional relevant studies referenced by these publications were included.


CONCLUSIONS
Both short- and long-term studies have consistently yielded favorable results for the use of TBZ in the treatment of hyperkinetic movement in terms of efficacy and safety. TBZ is most effective in reducing chorea (including Huntington's disease associated chorea), tic associated with Tourette's syndrome and tardive dyskinesias. Furthermore, TBZ might also have potential for use in other hyperkinetic disorders (e.g., myoclonus and dystonia), for which future clinical trials are needed.
Fasano
Alfonso
A
Università Cattolica del Sacro Cuore, Istituto di Neurologia, Largo Agostino Gemelli, 8-00168 Roma, Italy. alfonso.fasano@rm.unicatt.it
Bentivoglio
Anna Rita
AR
D018759:Adrenergic Uptake Inhibitors / Q000009:adverse effects / Q000627:therapeutic use*; D000818:Animals; D004347:Drug Interactions; D006801:Humans; D023421:Models, Animal; D009422:Nervous System Diseases / Q000188:drug therapy; D016032:Randomized Controlled Trials as Topic; D013747:Tetrabenazine / Q000009:adverse effects / Q000627:therapeutic use*
D018759:Adrenergic Uptake Inhibitors; D013747:Tetrabenazine